Patents Assigned to SHENYANG FUYANG PHARMACEUTICAL TECHNOLOGY CO., LTD .
  • Publication number: 20200405739
    Abstract: Disclosed are an mTOR inhibitor, a pharmaceutical composition and use thereof. The mTOR inhibitor includes one of carrimycin, isovalerylspiramycin I, isovalerylspiramycin II and isovalerylspiramycin III, or a combination of two or three of isovalerylspiramycin I, isovalerylspiramycin II and isovalerylspiramycin III. The pharmaceutical composition also includes a drug for treating and/or preventing diseases related to the mTOR pathway as a second active ingredient. The mTOR inhibitor has obvious inhibiting effect on cells of diseases related to mTOR pathway, and is used for preparing drugs for treating and/or preventing diseases related to the mTOR pathway.
    Type: Application
    Filed: January 18, 2019
    Publication date: December 31, 2020
    Applicant: SHENYANG FUYANG PHARMACEUTICAL TECHNOLOGY CO., LTD.
    Inventors: Mingyu XIA, Xiaofeng ZHAO, Xunlei JIANG, Xundong JIANG
  • Patent number: 10858659
    Abstract: The present disclosure provides a biosynthetic gene cluster of carrimycin. The biosynthetic gene cluster comprises 44 gene open reading frames (orf), i.e., 5 orfs (orf10-14) encoding polyketide synthase, 9 orfs (orf1, 4-6, 15 and 36-39) related to polyketone synthesis extension unit and modification, 16 orfs (orf9, 16-22, 24, 26, 28, 29, 33-35 and 41) related to glycosyl synthesis, 6 orfs (orf7, 8, 30-32 and 40) related to glycosyl transfer, 2 orfs (orf3 and 25) related to resistance, 4 orfs (orf2, 23, 27 and 42) possibly related to regulation, a tsr resistance marker gene orf (orf43) and a 4?-mycaroseglucoside isovaleryl transferase gene orf (orf44).
    Type: Grant
    Filed: November 24, 2016
    Date of Patent: December 8, 2020
    Assignee: SHENYANG FUYANG PHARMACEUTICAL TECHNOLOGY CO., LTD.
    Inventors: Yiguang Wang, Yang Jiang, Xiaofeng Zhao, Weiqing He, Jianlu Dai
  • Publication number: 20200338107
    Abstract: A medicament for preventing and/or treating a disease is disclosed, the disease is Alzheimer's disease, diabetes or senility; and the medicament includes a first active ingredient, and the first active ingredient includes one of carrimycin, isovalerylspiramycin I, isovalerylspiramycin II and isovalerylspiramycin III, or a combination of two or three of isovalerylspiramycin I, isovalerylspiramycin II and isovalerylspiramycin III.
    Type: Application
    Filed: January 18, 2019
    Publication date: October 29, 2020
    Applicant: SHENYANG FUYANG PHARMACEUTICAL TECHNOLOGY CO., LTD.
    Inventors: Mingyu XIA, Xiaofeng ZHAO, Xunlei JIANG, Xundong JIANG
  • Publication number: 20200163984
    Abstract: Disclosed are a medicament comprising isovaleryl spiramycin I, II and/or III, and use of isovaleryl spiramycin I, II and/or III in manufacturing medicament for treating and/or preventing tumor and the medicament.
    Type: Application
    Filed: July 4, 2018
    Publication date: May 28, 2020
    Applicant: SHENYANG FUYANG PHARMACEUTICAL TECHNOLOGY CO., LTD.
    Inventors: Enhong JIANG, Weiqing HE, Jianlu DAI, Yang JIANG, Xunlei JIANG, Xiaofeng ZHAO
  • Publication number: 20200030351
    Abstract: The present disclosure provides use of carrimycin and pharmaceutically acceptable salts thereof for the preparation of a medicament for the treatment of tumors. The carrimycin and the pharmaceutically acceptable salts thereof have good curative effects on breast cancer, liver cancer, lung cancer, renal cancer, brain tumor, cervical cancer, prostate cancer, pancreatic cancer, esophageal cancer, gastric adenocarcinoma, colon cancer, lymphoma or leukemia and other tumors, and especially have obvious inhibitory effects on the growth of human breast cancer cells MCF-7 and MDA-MB-231, human hepatoma cells HepG2, human non-small cell lung cancer cells A549, human large cell lung cancer cells H460 and H1299, human renal clear cell adenocarcinoma cell 786-O, human renal cell adenocarcinoma cell 769-P, and human glioma cell U251.
    Type: Application
    Filed: April 5, 2018
    Publication date: January 30, 2020
    Applicant: SHENYANG FUYANG PHARMACEUTICAL TECHNOLOGY CO., LTD.
    Inventors: Enhong JIANG, Mingyu XIA, Xunlei JIANG, Xundong JIANG
  • Publication number: 20190093112
    Abstract: The present disclosure provides a biosynthetic gene cluster of carrimycin. The biosynthetic gene cluster comprises 44 gene open reading frames (orf), i.e., 5 orfs (orf10-14) encoding polyketide synthase, 9 orfs (orf1, 4-6, 15 and 36-39) related to polyketone synthesis extension unit and modification, 16 orfs (orf9, 16-22, 24, 26, 28, 29, 33-35 and 41) related to glycosyl synthesis, 6 orfs (orf7, 8, 30-32 and 40) related to glycosyl transfer, 2 orfs (orf3 and 25) related to resistance, 4 orfs (orf2, 23, 27 and 42) possibly related to regulation, a tsr resistance marker gene orf (orf43) and a 4?-mycaroseglucoside isovaleryl transferase gene orf (orf44).
    Type: Application
    Filed: November 24, 2016
    Publication date: March 28, 2019
    Applicant: SHENYANG FUYANG PHARMACEUTICAL TECHNOLOGY CO., LTD.
    Inventors: Yiguang WANG, Yang JIANG, Xiaofeng ZHAO, Weiqing HE, Jianlu DAI
  • Publication number: 20190001160
    Abstract: Use of carrimycin in mycobacterium tuberculosis infection resistance comprises the main steps: measuring the activity of carrimycin in mycobacterium tuberculosis resistance by adopting an absolute concentration method through taking clinical first-line antituberculotics, i.e., isoniazid and rifampicin as controls. The result indicates that carrimycin has obvious superior activity to clinically-separated mycobacterium tuberculosis including drug-resistant bacteria compared with those of the clinical first-line control drugs, i.e., the isoniazid and the rifampicin, and use of carrimycin in manufacturing drugs for treating tubercle bacillus infected diseases are expected to be developed.
    Type: Application
    Filed: December 5, 2016
    Publication date: January 3, 2019
    Applicant: SHENYANG FUYANG PHARMACEUTICAL TECHNOLOGY CO., LTD .
    Inventors: Yiguang WANG, Yang JIANG, Xiaofeng ZHAO, Weiqing HE